Shared resource to develop tools and reagents to study structural polymorphisms in Abeta amyloid aggregates in AD

项目摘要 阿尔茨海默病(AD)目前是一种无法治愈的神经退行性疾病，影响着3500多万人 全世界，包括美国每分钟诊断出一例新病例的540万人。淀粉样蛋白出现 通常作为各种神经退行性疾病的关键病理特征，如AD和AUTHERY 30年的深入研究，关于其意义、机制和在发病机制中的作用的重要问题 淀粉样蛋白的比例仍未解决。由于淀粉样蛋白A？肽在家族性阿尔茨海默病中的强烈意义， 淀粉样蛋白聚集体(低聚物、纤维)的制备已被超过100,000篇出版物所介绍 过去的30年。在许多情况下，相互冲突、相互矛盾和不可重现的数据会混淆底层数据 发病机制。结构生物学的进展已经确立了几种不同的结构 淀粉样蛋白的类型，导致发现淀粉样蛋白结构与相同的蛋白质具有高度多态 层序采用明显的贝塔板褶皱。此外，不同的结构似乎与不同的 疾病亚型，说明结构变异在发病机制中起作用。这种多态和 结构的异质性也可能低估了困扰淀粉样蛋白的不可重复性和相互矛盾的结果。 研究。这表明，迫切需要具有良好特征的标准化方案来编制 不同类型的淀粉样蛋白A？聚集体和试剂来鉴定这些制剂并特异性地鉴定 并在体外和脑内对这些多态进行量化，以支持了解其作用的基础研究 淀粉样蛋白在疾病发病机制中的作用机制。因此，这一资源倡议的总体目标是 建立用于开发试剂和协议的来源网络， 淀粉样寡聚体和纤维的表征、鉴定以及这些材料的传播 调查人员。

Project Abstract Alzheimer’s disease (AD) is currently an incurable neurodegenerative disease that affects over 35 million people worldwide, including 5.4 million individuals in the USA with a new case diagnosed every minute. Amyloids occur commonly as key pathological features in a wide variety of neurodegenerative diseases such as AD and despite 30 years of intensive research, important questions about the significance, mechanisms and role in pathogenesis of amyloids remain unresolved. Because of the strong implication of amyloid Aß peptide in familial AD, preparations of amyloid aggregates (oligomers, fibrils) have been featured in over 100,000 publications over the past 30 years. In many cases, conflicting, contradictory and non-reproducible data obfuscate the underlying mechanisms of pathogenesis. Advances in structural biology have established the structures of several distinct types of amyloid, leading to the discovery that amyloid structures are highly polymorphic with the same protein sequence adopting distinct beta sheet folds. Moreover, different structures seem to correlate with different disease subtypes, indicating that structural variation plays a role in pathogenesis. This polymorphism and structural heterogeneity may also underly the irreproducibility and conflicting results that have plagued amyloid research. This suggests a critical need for well-characterized, standardized protocols for the preparation of different types of amyloid Aß aggregates and reagents to authenticate these preparations and specifically identify and quantify these polymorphs in vitro and in brain in order to support basic research to understand the roles and mechanisms of amyloids in disease pathogenesis. Therefore, the overall goal of this resource initiative is to establish a source network for the development of reagents and protocols for the production, standardization, characterization, authentication of amyloid oligomers and fibrils and the dissemination of these materials to investigators.